Amrad Corporation Limited

Millennium Pharmaceuticals Limited

Immunex Corporation

Millennium Biotherapeutics, Inc.

Millenium Pharmaceuticals, Inc.

David P Gearing

Nicos Anthony Nicola

Donald Metcalf

Nicholas Martin Gough

Richard John Simpson

Douglas James Hilton

Tracy Ann Willson

Sean Anthony McCarthy

Edouard C Nice

Julie Ann King

Douglas Adam Levinson

Julie A King

Samantha J Busfield

Patricia M Beckmann

M Patricia Beckmann

Sean A Mccarthy

The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Delta3 (tango24) protein and nucleic acid molecules and uses thereof

The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-&#x3b1;. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

EGF-like nucleic acids and polypeptides and uses thereof

The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-&#x3b1;. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The ELVIS nucleic acids of the present invention are useful as modulating agents in regulating a variety of cellular processes, and are particularly useful for diagnostic, screening and therapeutic methods for the treatment of skin conditions, such as for wound healing. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

EGF-like nucleic acids

The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; 8 transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library corresponding to the clone in the mammalian cell clone library identified in step (f); and (h) isolating and sequencing a portion of the mammalian cDNA present in the bacterial cell library clone identified in step (g) to identify a mammalian cDNA encoding a mammalian protein having a signal sequence.

Secreted neural adhesion proteins

The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; (c) transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library corresponding to the clone in the mammalian cell clone library identified in step (f); and (h) isolating and sequencing a portion of the mammalian cDNA present in the bacterial cell library clone identified in step (g) to identify a mammalian cDNA encoding a mammalian protein having a signal sequence.

Nucleic acid molecules encoding a secreted neural adhesion protein

The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

Leukaemia inhibitory factor

The invention provides a recombinant or synthetic receptor or a derivative thereof, for granulocyte-macrophage colony-stimulating factor (GM-CSF). The GM-CSF receptor is useful, inter alia, in the treatment or diagnosis of GM-CSF-related diseases, and in the screening of agonists and antagonists of GM-CSF receptors. The invention further provides antibodies directed against GM-CSF receptor or derivatives thereof, and pharmaceutical compositions comprising either the GM-CSF receptor, the receptor derivative, or an antibody thereto, and methods of using thereof.

Antibodies which bind granulocyte-macrophane colony-stimulating factor

The present invention relates to the identification and characterization of a novel gene called don-1 related to epidermal growth factors (EGF) such as the neuregulins, and methods of preparing and using alternate splice forms of this gene to express new Don-1 polypeptides.

Don-1 gene and polypeptides and uses therefor

The invention provides nucleic acid molecules which encode polypeptides having homology to proteins in the Delta family of proteins. The invention also provides vectors containing nucleic acid molecules of the invention and host cells containing the vectors.

Human Delta3 nucleic acid molecules

The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; (c) transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which express alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library corresponding to the clone in the mammalian cell clone library identified in step (f); and (h) isolating and sequencing a portion of the mammalian cDNA present in the bacterial cell library clone identified in step (g) to identify a mammalian cDNA encoding a mammalian protein having a signal sequence.

Method for identifying genes encoding secreted or membrane-associated

Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, and antibodies that are immunoreactive with LIF-R are disclosed.

Antibodies immunoreactive with leukemia inhibitory factor receptors

The present invention provides isolated DNA molecules encoding human and murine LIF, and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibody thereto.

Granulocyte-macrophage colony-stimulating factor receptor and

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibodies thereto.

Growing community of inventors

Seattle, WA, United States of America

David P Gearing